-
Mashup Score: 4
Researchers have identified a novel screening strategy to improve early detection of pancreatic cancer in high-risk patients.
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8Liposomal Irinotecan in First-Line Treatment of Metastatic Pancreatic Adenocarcinoma - The ASCO Post - 2 month(s) ago
On February 13, 2024, the U.S. Food and Drug Administration approved liposomal irinotecan (Onivyde) for use with oxaliplatin, fluorouracil, and leucovorin in the first-line treatment of metastatic pancreatic adenocarcinoma. 1 Approval was based on the open-label NAPOLI 3 trial (ClinicalTrials.gov identifier NCT04083235), in which 770 patients who had received no chemotherapy in the me tastatic setting were randomly assigned to receive the following treatments: NALIRIFOX: Liposomal irinotecan at 50 mg/m
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8Liposomal Irinotecan in First-Line Treatment of Metastatic Pancreatic Adenocarcinoma - The ASCO Post - 2 month(s) ago
On February 13, 2024, the U.S. Food and Drug Administration approved liposomal irinotecan (Onivyde) for use with oxaliplatin, fluorouracil, and leucovorin in the first-line treatment of metastatic pancreatic adenocarcinoma. 1 Approval was based on the open-label NAPOLI 3 trial (ClinicalTrials.gov identifier NCT04083235), in which 770 patients who had received no chemotherapy in the me tastatic setting were randomly assigned to receive the following treatments: NALIRIFOX: Liposomal irinotecan at 50 mg/m
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
In a Trans-Atlantic Pancreatic Surgery Consortium study reported in the Journal of Clinical Oncology, Dekker et al found that the “ABC” clinical staging system could be used to differentiate overall survival outcomes in patients with localized pancreatic ductal adenocarcinoma. The study included 1,835 patients treated with ini tial mFOLFIRINOX (modified fluorouracil with leucovorin, irinotecan, and oxaliplatin) at five high-volume pancreatic cancer centers in the United States and the Netherlands between
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4FDA Approves Irinotecan Liposome for the First-Line Treatment of Metastatic Pancreatic Adenocarcinoma - The ASCO Post - 3 month(s) ago
On February 13, the U.S. Food and Drug Administration (FDA) approved irinotecan liposome (Onivyde) with oxaliplatin, fluorouracil, and leucovorin for the first-line treatment of metastatic pancreatic adenocarcinoma. Efficacy was evaluated in NAPOLI-3 (ClinicalTrials.gov identifier NCT04083235), a randomized, multicenter, open-label, active-controlled trial in 770 patients with metastatic pancreatic adenocarcinoma who had not previously received chemotherapy in the metastatic setting. Random assignment
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5Gemcitabine/Paclitaxel vs Gemcitabine Alone After FOLFIRINOX in Metastatic Pancreatic Cancer - The ASCO Post - 4 month(s) ago
As reported in the Journal of Clinical Oncology by De La Fouchardière et al, the French phase III GEMPAX trial showed no overall survival benefit with second-line gemcitabine/paclitaxel vs gemcitabine alone after FOLFIRINOX (fluorouracil, oxaliplatin, and irinotecan) in pat ients with metastatic pancreatic ductal adenocarcinoma. In the multicenter open-label trial, 211 patients who had received prior FOLFIRINOX were randomly assigned 2:1 between June 2019 and March 2021 to receive gemcitabine at 1,000
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Intraductal Papillary Mucinous Neoplasms: Risk of Pancreatic Cancer - The ASCO Post - 6 month(s) ago
In a retrospective cohort study reported in JAMA Network Open, de la Fuente et al found that the risk of pancreatic cancer in patients with Fukuoka criteria–negative intraductal papillary mucinous neoplasms (F-N IPMNs) did not differ from that in patients without IPMNs. In addition, the small proportion of patients with pancreatic cancer associated with IPMNs (IPMN-PC) had better survival vs patients with non–IPMN PC. The study was conducted in Olmsted County, Minnesota, using the Rochester Epidemiology
Source: www.ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
Improving Early Detection of Pancreatic Cancer in High-Risk Patients https://t.co/CNIx1fu2lK #pancsm #pancreaticcancer #oncology